Longitudinal observation on CSF Aβ42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice

Neurobiology of Disease

Volumn 17, Issue 3, 2004, Pages 516-523

  Liu, Li ^a,b   Herukka, Sanna Kaisa ^a   Minkeviciene, Rimante ^a   Van Groen, Thomas ^a,c   Tanila, Heikki ^a,c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF CHICAGO   (United States)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Alzheimer's disease; Amyloid; Cerebrospinal fluid; Hippocampus; Transgenic mouse

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; PRESENILIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HIPPOCAMPUS; LONGITUDINAL STUDY; MALE; MOUSE; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; TRANSGENIC MOUSE;

AGING; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; COLONY-STIMULATING FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PRESENILIN-1; TIME FACTORS;

EID: 9644252796     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2004.08.005     Document Type: Article

References (35)

1. N. Andreasen, and K. Blennow Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease Peptides 23 2002 1205 1214
2. N. Andreasen, L. Minthon, E. Vanmechelen, H. Vanderstichele, P. Davidsson, B. Winblad, and K. Blennow Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment Neurosci. Lett. 273 1999 5 8
3. N. Andreasen, C. Hesse, P. Davidsson, L. Minthon, A. Wallin, B. Winblad, H. Vanderstichele, E. Vanmechelen, and K. Blennow Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease Arch. Neurol. 56 1999 673 680
4. D.R. Borchelt, J. Davis, M. Fischer, M.K. Lee, H.H. Slunt, T. Ratovitsky, J. Regard, N.G. Copeland, N.A. Jenkins, S.S. Sisodia, and D.L. Price A vector for expressing foreign genes in the brains and hearts of transgenic mice Genet. Anal. 13 1996 159 163
5. D.R. Borchelt, T. Ratovitski, J. van Lare, M.K. Lee, V. Gonzales, N.A. Jenkins, N.G. Copeland, D.L. Price, and S.S. Sisodia Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins Neuron 19 1997 939 945
6. M.E. Calhoun, P. Burgermeister, A.L. Phinney, M. Stalder, M. Tolnay, K.H. Wiederhold, D. Abramowski, C. Sturchler-Pierrat, B. Sommer, M. Staufenbiel, and M. Jucker Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid Proc. Natl. Acad. Sci. U. S. A. 96 1999 14088 14093
7. J.L. Cummings, H.V. Vinters, G.M. Cole, and Z.S. Khachaturian Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities Neurology 51 1998 S2 17 (discussion S65-17)
8. R.B. DeMattos, K.R. Bales, M. Parsadanian, M.A. O'Dell, E.M. Foss, S.M. Paul, and D.M. Holtzman Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease J. Neurochem. 81 2002 229 236
9. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 2002 353 356
10. A. Heyman, B. Peterson, G. Fillenbaum, and C. Pieper The consortium to establish a registry for Alzheimer's disease (CERAD). Part XIV: demographic and clinical predictors of survival in patients with Alzheimer's disease Neurology 46 1996 656 660
11. D.M. Holtzman, K.R. Bales, S.M. Paul, and R.B. DeMattos Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease Adv. Drug Deliv. Rev. 54 2002 1603 1613
12. J.L. Jankowsky, D.J. Fadale, J. Anderson, G.M. Xu, V. Gonzales, N.A. Jenkins, N.G. Copeland, M.K. Lee, L.H. Younkin, S.L. Wagner, S.G. Younkin, and D.R. Borchelt Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase Hum. Mol. Genet. 13 2004 159 170
13. C. Janus, and D. Westaway Transgenic mouse models of Alzheimer's disease Physiol. Behav. 73 2001 873 886
14. M. Jensen, J. Schroder, M. Blomberg, B. Engvall, J. Pantel, N. Ida, H. Basun, L.O. Wahlund, E. Werle, M. Jauss, K. Beyreuther, L. Lannfelt, and T. Hartmann Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression Ann. Neurol. 45 1999 504 511
15. K. Johnson-Wood, M. Lee, R. Motter, K. Hu, G. Gordon, R. Barbour, K. Khan, M. Gordon, H. Tan, D. Games, I. Lieberburg, D. Schenk, P. Seubert, and L. McConlogue Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease Proc. Natl. Acad. Sci. U. S. A. 94 1997 1550 1555
16. T. Kawarabayashi, L.H. Younkin, T.C. Saido, M. Shoji, K.H. Ashe, and S.G. Younkin Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease J. Neurosci. 21 2001 372 381
17. M. Kraszpulski, H. Soininen, S. Helisalmi, and I. Alafuzoff The load and distribution of beta-amyloid in brain tissue of patients with Alzheimer's disease Acta Neurol. Scand. 103 2001 88 92
18. L. Lannfelt Biochemical diagnostic markers to detect early Alzheimer's disease Neurobiol. Aging 19 1998 165 167
19. L. Lannfelt, H. Basun, C. Vigo-Pelfrey, L.O. Wahlund, B. Winblad, I. Lieberburg, and D. Schenk Amyloid beta-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation Neurosci. Lett. 199 1995 203 206
20. L. Liu, S. Ikonen, T. Tapiola, H. Tanila, and T. van Groen Fimbria-fornix lesion does not affect APP levels and amyloid deposition in the hippocampus of APP+PS1 double transgenic mice Exp. Neurol. 177 2002 565 574
21. L. Liu, S. Ikonen, T. Heikkinen, T. Tapiola, T. van Groen, and H. Tanila The effects of long-term treatment with metrifonate, a cholinesterase inhibitor, on cholinergic activity, amyloid pathology, and cognitive function in APP and PS1 doubly transgenic mice Exp. Neurol. 173 2002 196 204
22. L. Liu, T. Tapiola, S.K. Herukka, M. Heikkila, and H. Tanila Abeta levels in serum, CSF and brain, and cognitive deficits in APP + PS1 transgenic mice NeuroReport 14 2003 163 166
23. M. Maruyama, H. Arai, M. Sugita, H. Tanji, M. Higuchi, N. Okamura, T. Matsui, S. Higuchi, S. Matsushita, H. Yoshida, and H. Sasaki Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease Exp. Neurol. 172 2001 433 436
24. U. Meyding-Lamade, K. Ehrhart, H.L. de Ruiz, R. Kehm, and W. Lamade A new technique: serial puncture of the cisterna magna for obtaining cerebrospinal fluid in the mouse-application in a model of herpes simplex virus encephalitis J. Exp. Anim. Sci. 38 1996 77 81
25. M. Pitschke, R. Prior, M. Haupt, and D. Riesner Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy Nat. Med. 4 1998 832 834
26. D.L. Price, and S.S. Sisodia Mutant genes in familial Alzheimer's disease and transgenic models Annu. Rev. Neurosci. 21 1998 479 505
27. J. Puolivali, J. Wang, T. Heikkinen, M. Heikkila, T. Tapiola, T. van Groen, and H. Tanila Hippocampal A beta 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice Neurobiol. Dis. 9 2002 339 347
28. M. Riemenschneider, N. Lautenschlager, S. Wagenpfeil, J. Diehl, A. Drzezga, and A. Kurz Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment Arch. Neurol. 59 2002 1729 1734
29. J. Rogers, and J.H. Morrison Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease J. Neurosci. 5 1985 2801 2808
30. D.J. Selkoe Alzheimer's disease: genes, proteins, and therapy Physiol. Rev. 81 2001 741 766
31. M. Sjogren, N. Andreasen, and K. Blennow Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers Clin. Chim. Acta 332 2003 1 10
32. C.E. Teunissen, J. de Vente, H.W. Steinbusch, and C. De Bruijn Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid Neurobiol. Aging 23 2002 485 508
33. T. van Groen, L. Liu, S. Ikonen, and I. Kadish Diffuse amyloid deposition, but not plaque number, is reduced in amyloid precursor protein/presenilin 1 double-transgenic mice by pathway lesions Neuroscience 119 2003 1185 1197
34. J. Wang, S. Ikonen, K. Gurevicius, T. Van Groen, and H. Tanila Altered auditory-evoked potentials in mice carrying mutated human amyloid precursor protein and presenilin-1 transgenes Neuroscience 116 2003 511 517
35. H.L. Weiner, C.A. Lemere, R. Maron, E.T. Spooner, T.J. Grenfell, C. Mori, S. Issazadeh, W.W. Hancock, and D.J. Selkoe Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease Ann. Neurol. 48 2000 567 579